Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.41 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.41 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.41 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | PCNA | P12004 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492386 | 1.00 | KMT2A (0.46) | KMT2AATMCYP3A4PLAAT3PLAAT5 | |
| SCHEMBL6488494 | 0.83 | ATM (0.49) | ATMCYP3A4ITGB3ITGA2BPCNA | |
| SCHEMBL7688482 | 0.83 | ATM (0.49) | ATMCYP3A4ITGB3ITGA2BPCNA | |
| SCHEMBL6488460 | 0.82 | GRN (0.46) | ATMITGB3ITGA2BPCNAP2RX3 | |
| SCHEMBL6488465 | 0.82 | GRN (0.46) | ATMITGB3ITGA2BPCNAP2RX3 | |
| SCHEMBL6478695 | 0.82 | KDM4E (0.48) | ATMITGB3ITGA2BPCNAKDM4E | |
| SCHEMBL6478699 | 0.82 | KDM4E (0.48) | ATMITGB3ITGA2BPCNAKDM4E | |
| SCHEMBL6478754 | 0.81 | LMNA (0.47) | ATMITGB3ITGA2BPCNAP2RX3 | |
| SCHEMBL6478751 | 0.81 | LMNA (0.47) | ATMITGB3ITGA2BPCNAP2RX3 | |
| SCHEMBL7685194 | 0.80 | PCNA (0.47) | ATMCYP3A4ITGB3ITGA2BPCNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | KMT2A 2316/4885ATM 3918/4885CYP3A4 754/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | KMT2A 1858/4885ATM 3785/4885CYP3A4 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.